PT  - JOURNAL ARTICLE
AU  - Padilha, Dayane Azevedo
AU  - Barazzetti, Fernando Hartmann
AU  - Schörner, Marcos André
AU  - Filho, Vilmar Benetti
AU  - Kawagoe, Eric Kazuo
AU  - Marques Souza, Doris Sobral
AU  - Bazzo, Maria Luiza
AU  - Wagner, Glauber
AU  - Fongaro, Gislaine
TI  - MONITORING OF RESPIRATORY VIRUS COINFECTION IN SOUTHERN BRAZIL DURING COVID-19 PANDEMIC
AID  - 10.1101/2024.04.09.24305542
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.09.24305542
4099  - http://medrxiv.org/content/early/2024/04/12/2024.04.09.24305542.short
4100  - http://medrxiv.org/content/early/2024/04/12/2024.04.09.24305542.full
AB  - Since December 2019, the COVID-19 pandemic caused by SARS-CoV-2 has reached approximately 769 million people, leading to more than 7 million deaths worldwide. Faced with the possible presence of other respiratory pathogens that could co-infect and modify the clinical response of patients detected for SARS-CoV-2, some researchers have explored this line of investigation. The relationship between these co-infections remains unclear, leading to a need to deepen our knowledge about interactions among pathogens, and between pathogens and the host. Thus, the present study employed RT-qPCR to assess the presence of Human Adenovirus (HAdV), Influenza A (Flu A), Influenza B (Flu B), Human Metapneumovirus (HMPV), Respiratory Syncytial Virus (RSV), Human Rhinovirus (HRV), and Parainfluenza Virus (PIV). A total of 187 nasopharyngeal samples from adult patients exhibiting respiratory symptoms were collected between February 2021 and November 2022 at the University Hospital Polydoro Ernani de Sao Thiago in Florianopolis, SC, Brazil. Our findings revealed that 25.16% of samples tested positive for non-SARS-CoV-2 respiratory viruses (29.8% - HRV, 5.3% - PIV, 4.3%-RSV, and 1.1% - HMPV). From the 74.84% of SARS-CoV-2 positive patients, the presence of co-infection was observed in 9,7% of patients, with 7.5% being HRV, 1.1% HAdV and 1.1% Flu A. Since co-infections can potentially alter patient prognoses and impact local epidemiological dynamics, this study highlights the significance of ongoing monitoring and epidemiological assessment through genomic surveillance of other clinically relevant respiratory pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Santa Catarina Research and Innovation Foundation (FAPESC, Santa Catarina, Brazil) (grant number COV2020051000065), CAPES (Coordination for the Improvement of Higher Education Personnel, Brazil), CNPq (National Council for Scientific and Technological Development, Brazil) and UFSC (Federal University of Santa Catarina). DAP, FHB, MAS, VBF, EKK and DSMS were recipients of FAPESC, CAPES, or CNPq scholarships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee in Research Humans Beings of Federal University of Santa Catarina (Assent number: 4.035.636, CAAE: 31521920.8.0000.0121, 19 May 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript